PL2141172T3 - Cyklopropylowe inhibitory polimerazy - Google Patents

Cyklopropylowe inhibitory polimerazy

Info

Publication number
PL2141172T3
PL2141172T3 PL09008634T PL09008634T PL2141172T3 PL 2141172 T3 PL2141172 T3 PL 2141172T3 PL 09008634 T PL09008634 T PL 09008634T PL 09008634 T PL09008634 T PL 09008634T PL 2141172 T3 PL2141172 T3 PL 2141172T3
Authority
PL
Poland
Prior art keywords
cyclopropyl
polymerase inhibitors
polymerase
inhibitors
cyclopropyl polymerase
Prior art date
Application number
PL09008634T
Other languages
English (en)
Inventor
Tim Hugo Maria Jonckers
Pierre Jean-Marie Bernard Raboisson
Koen Vandyck
Original Assignee
Janssen Products Lp
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41095413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2141172(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Products Lp, Medivir Ab filed Critical Janssen Products Lp
Publication of PL2141172T3 publication Critical patent/PL2141172T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/073Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL09008634T 2008-07-01 2009-07-01 Cyklopropylowe inhibitory polimerazy PL2141172T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08159396 2008-07-01
EP08171005 2008-12-08
EP09008634A EP2141172B1 (en) 2008-07-01 2009-07-01 Cyclopropyl polymerase inhibitors

Publications (1)

Publication Number Publication Date
PL2141172T3 true PL2141172T3 (pl) 2013-03-29

Family

ID=41095413

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09008634T PL2141172T3 (pl) 2008-07-01 2009-07-01 Cyklopropylowe inhibitory polimerazy

Country Status (29)

Country Link
US (1) US8431588B2 (pl)
EP (1) EP2141172B1 (pl)
JP (1) JP5624029B2 (pl)
KR (1) KR20110038683A (pl)
CN (2) CN102083845B (pl)
AP (1) AP2010005505A0 (pl)
AR (1) AR072428A1 (pl)
AU (1) AU2009266004B2 (pl)
BR (1) BRPI0913643A2 (pl)
CA (1) CA2729316A1 (pl)
CL (1) CL2010001634A1 (pl)
CO (1) CO6321255A2 (pl)
DK (1) DK2141172T3 (pl)
EA (1) EA022754B1 (pl)
EC (1) ECSP10010725A (pl)
ES (1) ES2396803T3 (pl)
HK (1) HK1226080A1 (pl)
HR (1) HRP20121068T1 (pl)
IL (1) IL209932A (pl)
MX (1) MX2010014493A (pl)
NI (1) NI201000231A (pl)
PL (1) PL2141172T3 (pl)
PT (1) PT2141172E (pl)
SI (1) SI2141172T1 (pl)
SV (1) SV2010003779A (pl)
TW (1) TW201012814A (pl)
UY (1) UY31950A (pl)
WO (1) WO2010000459A1 (pl)
ZA (1) ZA201009294B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736482C (en) * 2008-09-08 2018-01-02 Novomer, Inc. Polycarbonate polyol compositions and methods
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
EA201390988A1 (ru) 2010-12-30 2014-04-30 Энанта Фармасьютикалз, Инк. Фенантридиновые макроциклические ингибиторы сериновой протеазы вируса гепатита c
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP5845841B2 (ja) 2011-11-18 2016-01-20 東芝ライテック株式会社 照明制御装置
US8673926B2 (en) 2012-02-14 2014-03-18 University Of Georgia Research Foundation, Inc. Spiro[2.4]heptanes for treatment of flaviviridae infections
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
RU2590952C1 (ru) * 2015-05-26 2016-07-10 Вячеслав Энгельсович Семёнов Средство гепатопротекторного действия
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
IL288737B (en) 2017-02-01 2022-09-01 Atea Pharmaceuticals Inc Hemisulfate nucleotide salt for treatment of hepatitis c virus
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
IL308921A (en) 2021-06-17 2024-01-01 Atea Pharmaceuticals Inc Combination anti-HCV therapy is beneficial

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2170020C (en) 1992-12-29 2005-08-02 Dale J. Kempf Retroviral protease inhibiting compounds
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
TW200500375A (en) * 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
EA014685B1 (ru) * 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
WO2006021341A1 (en) * 2004-08-23 2006-03-02 F. Hoffmann-La Roche Ag Antiviral 4’-azido-nucleosides
AP2009004812A0 (en) 2006-10-10 2009-04-30 Medivir Ab HCV nucleoside inhibitor

Also Published As

Publication number Publication date
KR20110038683A (ko) 2011-04-14
US8431588B2 (en) 2013-04-30
HK1226080A1 (zh) 2017-09-22
JP2011526270A (ja) 2011-10-06
AU2009266004A1 (en) 2010-01-07
SV2010003779A (es) 2011-02-08
HRP20121068T1 (hr) 2013-01-31
SI2141172T1 (sl) 2013-02-28
WO2010000459A1 (en) 2010-01-07
EA201170118A1 (ru) 2011-06-30
TW201012814A (en) 2010-04-01
MX2010014493A (es) 2011-05-19
IL209932A (en) 2013-12-31
AU2009266004B2 (en) 2014-01-30
CN105693794A (zh) 2016-06-22
CN102083845A (zh) 2011-06-01
ES2396803T3 (es) 2013-02-27
NI201000231A (es) 2011-09-03
CA2729316A1 (en) 2010-01-07
AR072428A1 (es) 2010-08-25
DK2141172T3 (da) 2013-01-21
ECSP10010725A (es) 2011-04-29
JP5624029B2 (ja) 2014-11-12
IL209932A0 (en) 2011-02-28
CO6321255A2 (es) 2011-09-20
UY31950A (es) 2010-01-29
EA022754B1 (ru) 2016-02-29
CN102083845B (zh) 2016-09-14
AP2010005505A0 (en) 2010-12-31
PT2141172E (pt) 2013-01-14
CL2010001634A1 (es) 2011-08-05
ZA201009294B (en) 2012-06-27
EP2141172B1 (en) 2012-10-24
BRPI0913643A2 (pt) 2015-11-24
EP2141172A1 (en) 2010-01-06
US20110092460A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
HUS2000024I1 (hu) Béta laktamáz inhibitorok
ZA201009294B (en) Cyclopropyl polymerase inhibitors
IL211070A0 (en) Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase
IL205064A0 (en) Viral polymerase inhibitors
EP2396004A4 (en) SELECTIVE KINASE HEMMER
IL211018A0 (en) Novel inhibitors
IL212897A0 (en) Uracyl cyclopropyl nucleotides
EP2185539A4 (en) VIRAL POLYMERASE INHIBITORS
EP2350039A4 (en) INHIBITORS OF VIRAL POLYMERASE
GB0901898D0 (en) Dual calpain-ros inhibitors
EP2188274A4 (en) VIRAL POLYMERASE HEMMER
ZA201303410B (en) Viral polymerase inhibitors
ZA201102837B (en) Phosphodiestarase inhibitors
GB0810011D0 (en) 5-Lipoxygenase inhibitors
GB0901900D0 (en) Dual calpain-ros inhibitors
GB0806919D0 (en) Polymerase inhibitors
GB0806914D0 (en) Polymerase inhibitors
GB0806911D0 (en) Polymerase inhibitors
GB0806912D0 (en) Polymerase inhibitors
GB0806913D0 (en) Polymerase inhibitors
GB0806920D0 (en) Polymerase inhibitors
GB0806917D0 (en) Polymerase inhibitors
GB0806915D0 (en) Polymerase inhibitors
GB0714941D0 (en) Inhibitors
GB201019387D0 (en) Inhibitors